Inari Medical Announces Leadership Succession Plan

August 3, 2022—Inari Medical, Inc., a device company focused on treatment of venous and other diseases, announced that Chief Operating Officer Drew Hykes will succeed Bill Hoffman as Chief Executive Officer (CEO), effective January 1, 2023. Mr. Hykes will join Inari’s Board of Directors. Mr. Hoffman will also continue to serve on the Board.

In the company’s press release, Mr. Hoffman stated, “Drew is a talented leader, and he is the single best problem solver I’ve ever seen. More important, he is committed to the beautiful simplicity of our mission to impact the lives of our patients and their families in extraordinary ways, and to take care of our people along the way.”

Mr. Hoffman continued, “Drew has established the scalable and repeatable systems that have produced best-in-class growth in patient treatments and revenue, and he has developed the cross-functional processes that have resulted in the explosion of new products and new markets we are just beginning to see. His leadership style and his skill set could not be better suited to the complexities that our next phase of growth will require. I am personally excited to have a front row seat to watch him lead the best team in the medical device space.”

According to the company, Mr. Hykes joined Inari in 2017 as Chief Commercial Officer and has served as the company’s Chief Operating Officer since 2020. Before joining Inari, he served in various leadership roles at both public and private medical device companies.

From 2012 to 2016, Mr. Hykes served as the Vice President of Commercial Operations at Sequent Medical where he led the commercialization strategy for the Web aneurysm embolization system from early prototype to broad adoption in the European market. Sequent was acquired by Terumo Corporation in July 2016.

Before Sequent, Mr. Hykes worked for 11 years at Medtronic and 4 years at ABN AMRO bank in Chicago, Illinois, focused on health care transactions. Mr. Hykes holds a BBA in Finance from the University of Wisconsin in Madison, Wisconsin, and an MBA from Harvard Business School in Boston, Massachusetts.

Mr. Hykes stated, “I am incredibly humbled to be named as Inari’s next CEO. Inari has undergone tremendous growth and change since I joined in 2017. From a venture backed, precommercial start up to an established public company with over 1,000 Clot Warriors, increasingly broad-based capabilities, and a shared ambition to change lives in the venous space and beyond. Despite all these changes, thanks to Bill’s leadership, we have maintained an unwavering commitment to our patients, our people and to big ideas. I couldn’t be more committed to these same ideals, nor more enthusiastic about this next phase of our growth.”

Inari’s products are designed for the treatment of the two distinct manifestations of venous thromboembolism: deep vein thrombosis and pulmonary embolism. The ClotTriever system received FDA 510(k) clearance and European CE Mark approval for the nonsurgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system has 510(k) clearance and CE Mark approval for the nonsurgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium, advised the company.